Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment

Aimée R. Kreimer, Mark Schiffman, Rolando Herrero, Allan Hildesheim, Paula González, Robert D. Burk, Carolina Porras, Mark E. Sherman, Franklin Demuth, Li Cheung, Concepciõn Bratti, Ana Cecilia Rodríguez

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Risk of recurrent CIN2+ (including cervical intraepithelial neoplasia grade 2 [CIN2], CIN3, carcinoma and in situ, adenocarcinoma in situ or cancer) remains elevated for years following treatment. The role of long-term post-treatment human papillomavirus (HPV) presence on subsequent risk of CIN2+ was evaluated in the 10,049-women Guanacaste cohort. Six hundred eighty-one women were referred to colposcopy because of high-grade cytology, positive cervicography and/or suspicion of cancer based on visual assessment; 486 were judged to require treatment. After excluding women with <12 months of follow-up (N = 88), prior cancer or hysterectomy (N = 37) or other reasons (N = 14), 347 were included in the analysis. Infections were categorized as persistent if present at both pre- and post-treatment visits and new if detected only post-treatment. Median time between the treatment and post-treatment visits was 6.7 years (interquartile range 3.8-7.8). At the post-treatment visit, 8 (2.4%), 2 (0.6%) and 8 (2.4%) of the 347 treated women had persistent HPV16, HPV18 or other carcinogenic HPV, respectively. Two (0.8%), 3 (1.0%) and 13 (4.0%) had new HPV16, HPV18 and other carcinogenic HPV, respectively. Six CIN2+ cases were identified at the post-treatment visit, all with persistent infections (three HPV16, one HPV18 and two other carcinogenic HPV). No recurrent disease was observed among women with new HPV infections during the follow-up period. Thus, persistence of HPV infection a median of six years after treatment was uncommon but, when present, posed a substantial risk of subsequent CIN2+. Serial follow-up data from other studies would further strengthen these conclusions.

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalInternational Journal of Cancer
Volume131
Issue number1
DOIs
StatePublished - Jul 1 2012

Fingerprint

Papillomavirus Infections
Cervical Intraepithelial Neoplasia
Neoplasms
Therapeutics
Colposcopy
Carcinoma in Situ
Infection
Hysterectomy
Cell Biology

Keywords

  • cervical pre-cancer
  • HPV
  • LEEP
  • post-treatment
  • recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. / Kreimer, Aimée R.; Schiffman, Mark; Herrero, Rolando; Hildesheim, Allan; González, Paula; Burk, Robert D.; Porras, Carolina; Sherman, Mark E.; Demuth, Franklin; Cheung, Li; Bratti, Concepciõn; Cecilia Rodríguez, Ana.

In: International Journal of Cancer, Vol. 131, No. 1, 01.07.2012, p. 211-218.

Research output: Contribution to journalArticle

Kreimer, AR, Schiffman, M, Herrero, R, Hildesheim, A, González, P, Burk, RD, Porras, C, Sherman, ME, Demuth, F, Cheung, L, Bratti, C & Cecilia Rodríguez, A 2012, 'Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment', International Journal of Cancer, vol. 131, no. 1, pp. 211-218. https://doi.org/10.1002/ijc.26349
Kreimer, Aimée R. ; Schiffman, Mark ; Herrero, Rolando ; Hildesheim, Allan ; González, Paula ; Burk, Robert D. ; Porras, Carolina ; Sherman, Mark E. ; Demuth, Franklin ; Cheung, Li ; Bratti, Concepciõn ; Cecilia Rodríguez, Ana. / Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. In: International Journal of Cancer. 2012 ; Vol. 131, No. 1. pp. 211-218.
@article{411f1b3311e14f0db85476448d124829,
title = "Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment",
abstract = "Risk of recurrent CIN2+ (including cervical intraepithelial neoplasia grade 2 [CIN2], CIN3, carcinoma and in situ, adenocarcinoma in situ or cancer) remains elevated for years following treatment. The role of long-term post-treatment human papillomavirus (HPV) presence on subsequent risk of CIN2+ was evaluated in the 10,049-women Guanacaste cohort. Six hundred eighty-one women were referred to colposcopy because of high-grade cytology, positive cervicography and/or suspicion of cancer based on visual assessment; 486 were judged to require treatment. After excluding women with <12 months of follow-up (N = 88), prior cancer or hysterectomy (N = 37) or other reasons (N = 14), 347 were included in the analysis. Infections were categorized as persistent if present at both pre- and post-treatment visits and new if detected only post-treatment. Median time between the treatment and post-treatment visits was 6.7 years (interquartile range 3.8-7.8). At the post-treatment visit, 8 (2.4{\%}), 2 (0.6{\%}) and 8 (2.4{\%}) of the 347 treated women had persistent HPV16, HPV18 or other carcinogenic HPV, respectively. Two (0.8{\%}), 3 (1.0{\%}) and 13 (4.0{\%}) had new HPV16, HPV18 and other carcinogenic HPV, respectively. Six CIN2+ cases were identified at the post-treatment visit, all with persistent infections (three HPV16, one HPV18 and two other carcinogenic HPV). No recurrent disease was observed among women with new HPV infections during the follow-up period. Thus, persistence of HPV infection a median of six years after treatment was uncommon but, when present, posed a substantial risk of subsequent CIN2+. Serial follow-up data from other studies would further strengthen these conclusions.",
keywords = "cervical pre-cancer, HPV, LEEP, post-treatment, recurrence",
author = "Kreimer, {Aim{\'e}e R.} and Mark Schiffman and Rolando Herrero and Allan Hildesheim and Paula Gonz{\'a}lez and Burk, {Robert D.} and Carolina Porras and Sherman, {Mark E.} and Franklin Demuth and Li Cheung and Concepci{\~o}n Bratti and {Cecilia Rodr{\'i}guez}, Ana",
year = "2012",
month = "7",
day = "1",
doi = "10.1002/ijc.26349",
language = "English (US)",
volume = "131",
pages = "211--218",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment

AU - Kreimer, Aimée R.

AU - Schiffman, Mark

AU - Herrero, Rolando

AU - Hildesheim, Allan

AU - González, Paula

AU - Burk, Robert D.

AU - Porras, Carolina

AU - Sherman, Mark E.

AU - Demuth, Franklin

AU - Cheung, Li

AU - Bratti, Concepciõn

AU - Cecilia Rodríguez, Ana

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Risk of recurrent CIN2+ (including cervical intraepithelial neoplasia grade 2 [CIN2], CIN3, carcinoma and in situ, adenocarcinoma in situ or cancer) remains elevated for years following treatment. The role of long-term post-treatment human papillomavirus (HPV) presence on subsequent risk of CIN2+ was evaluated in the 10,049-women Guanacaste cohort. Six hundred eighty-one women were referred to colposcopy because of high-grade cytology, positive cervicography and/or suspicion of cancer based on visual assessment; 486 were judged to require treatment. After excluding women with <12 months of follow-up (N = 88), prior cancer or hysterectomy (N = 37) or other reasons (N = 14), 347 were included in the analysis. Infections were categorized as persistent if present at both pre- and post-treatment visits and new if detected only post-treatment. Median time between the treatment and post-treatment visits was 6.7 years (interquartile range 3.8-7.8). At the post-treatment visit, 8 (2.4%), 2 (0.6%) and 8 (2.4%) of the 347 treated women had persistent HPV16, HPV18 or other carcinogenic HPV, respectively. Two (0.8%), 3 (1.0%) and 13 (4.0%) had new HPV16, HPV18 and other carcinogenic HPV, respectively. Six CIN2+ cases were identified at the post-treatment visit, all with persistent infections (three HPV16, one HPV18 and two other carcinogenic HPV). No recurrent disease was observed among women with new HPV infections during the follow-up period. Thus, persistence of HPV infection a median of six years after treatment was uncommon but, when present, posed a substantial risk of subsequent CIN2+. Serial follow-up data from other studies would further strengthen these conclusions.

AB - Risk of recurrent CIN2+ (including cervical intraepithelial neoplasia grade 2 [CIN2], CIN3, carcinoma and in situ, adenocarcinoma in situ or cancer) remains elevated for years following treatment. The role of long-term post-treatment human papillomavirus (HPV) presence on subsequent risk of CIN2+ was evaluated in the 10,049-women Guanacaste cohort. Six hundred eighty-one women were referred to colposcopy because of high-grade cytology, positive cervicography and/or suspicion of cancer based on visual assessment; 486 were judged to require treatment. After excluding women with <12 months of follow-up (N = 88), prior cancer or hysterectomy (N = 37) or other reasons (N = 14), 347 were included in the analysis. Infections were categorized as persistent if present at both pre- and post-treatment visits and new if detected only post-treatment. Median time between the treatment and post-treatment visits was 6.7 years (interquartile range 3.8-7.8). At the post-treatment visit, 8 (2.4%), 2 (0.6%) and 8 (2.4%) of the 347 treated women had persistent HPV16, HPV18 or other carcinogenic HPV, respectively. Two (0.8%), 3 (1.0%) and 13 (4.0%) had new HPV16, HPV18 and other carcinogenic HPV, respectively. Six CIN2+ cases were identified at the post-treatment visit, all with persistent infections (three HPV16, one HPV18 and two other carcinogenic HPV). No recurrent disease was observed among women with new HPV infections during the follow-up period. Thus, persistence of HPV infection a median of six years after treatment was uncommon but, when present, posed a substantial risk of subsequent CIN2+. Serial follow-up data from other studies would further strengthen these conclusions.

KW - cervical pre-cancer

KW - HPV

KW - LEEP

KW - post-treatment

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=84860222116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860222116&partnerID=8YFLogxK

U2 - 10.1002/ijc.26349

DO - 10.1002/ijc.26349

M3 - Article

C2 - 21823117

AN - SCOPUS:84860222116

VL - 131

SP - 211

EP - 218

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -